Status:
COMPLETED
Cryotherapy Intervention for Docetaxel-induced Nail Toxicities
Lead Sponsor:
Princess Alexandra Hospital, Brisbane, Australia
Conditions:
Effects of Chemotherapy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Between 30% and 88% of chemotherapy patients receiving docetaxel experience side effects of the hand ranging from skin and nail disfigurement, blistering, desquamation, pain, infection, and impaired t...
Detailed Description
Research problem: Internationally, cryotherapy for docetaxel-induced nail and skin toxicities of the hand has become a popular primary treatment. Yet there is little evidence beyond one Phase II, non...
Eligibility Criteria
Inclusion
- patients receiving docetaxel as mono- or combination therapy
- patients with no nail disorders at the start of treatment
- life expectancy of at least 3 months
Exclusion
- patients previously treated with taxane chemotherapy
- Raynaud's phenomenon
- distal metastases
- ungual pathology
- arteriopathy
- cold intolerance
- peripheral neuropathy of grade 2 or higher
- patients currently enrolled in clinical trials
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT00911352
Start Date
October 1 2010
End Date
December 1 2012
Last Update
December 5 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia, 4102